Back to top

Apogee acquisition is ‘net negative’ for Regeneron, says RBC Capital

RBC Capital keeps a Sector Perform rating and a $707 price target on Regeneron (REGN) but notes that the acquisition of Apogee Therapeutics (APGE) ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

AbbVie Inc. (ABBV)

Apogee Therapeutics Inc. (APGE)

Regeneron Pharmaceuticals, Inc. (REGN)